Breaking News Instant updates and real-time market news.

NTLA

Intellia Therapeutics

$22.71

0.69 (3.13%)

, EDIT

Editas Medicine

$33.59

-0.33 (-0.97%)

12:25
01/08/18
01/08
12:25
01/08/18
12:25

Intellia downplays gene paper amid share decline, STAT reports

Intellia Therapeutics (NTLA) pushed back against an unpublished paper posted Friday on bioRxiv that raised concerns about pre-existing immune responses to CRISPR-based therapies, Andrew Joseph of STAT reports. The company said the issues outlined in the study were either already being addressed or were not relevant to the medicines being developed. Shares of Intellia are down 19% to $18.48 in midday trading while Editas Medicine (EDIT) is down 16% to $28.28 and Crispr Therapeutics (CRSP) is down 5% to $25.45. Reference Link

NTLA

Intellia Therapeutics

$22.71

0.69 (3.13%)

EDIT

Editas Medicine

$33.59

-0.33 (-0.97%)

CRSP

Crispr Therapeutics

$26.81

2.9 (12.13%)

  • 08

    Jan

  • 08

    Jan

  • 26

    Feb

NTLA Intellia Therapeutics
$22.71

0.69 (3.13%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Intellia Therapeutics initiated with an Overweight at Barclays
Barclays initiated Intellia with an Overweight rating and $29 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
08/29/17
08/29/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JA Solar (JASO) downgraded to Sell from Hold at Axiom with analyst Gordon Johnson saying recent results suggest that Chinese module vendors are not benefiting significantly from any U.S. demand pull-in. 2. Finish Line (FINL) was downgraded to Sell from Neutral at Citi and Deutsche Bank, while being downgraded to Underperform from Neutral at Buckingham, and to Neutral from Buy at FBR Capital. 3. Intellia Therapeutics (NTLA) downgraded to Neutral from Buy at Chardan with analyst Madhu Kumar citing relative valuation. 4. Loxo Oncology (LOXO) downgraded to Market Perform from Outperform at JMP Securities with analyst Michael King saying he believes the company's platform and assets under development are now being fairly valued with the stock having risen above his $71 price target. 5. Cemex (CX) downgraded to Neutral from Buy at BofA/Merrill with analyst Carlos Peyrelongue citing lack of positive catalysts and risk of disappointment in Mexico and the U.S. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/17
JEFF
10/31/17
NO CHANGE
Target $42
JEFF
Buy
Intellia Therapeutics price target raised to $42 from $36 at Jefferies
10/31/17
LEER
10/31/17
NO CHANGE
Target $37
LEER
Outperform
Intellia Therapeutics price target raised to $37 from $29 at Leerink
Leerink analyst Joseph Schwartz said Intellia Therapeutics' (NTLA) demonstration of gene editing across multiple animal models brings the company one-step closer to an IND filing. He also believes investors are pricing in an M&A premium following Gilead's (GILD) acquisition of Kite and the approvals of Novartis' (NVS) Kymriah and Gilead's Yescarta. Noting that his valuation "now incorporates a very small fraction" of the Kite acquisition value, he raised his price target on Intellia to $37 from $29 and keeps an Outperform rating on the shares.
EDIT Editas Medicine
$33.59

-0.33 (-0.97%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Editas Medicine initiated with an Overweight at Barclays
Barclays initiated Editas Medicine with an Overweight rating and a $28 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
CRSP Crispr Therapeutics
$26.81

2.9 (12.13%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Crispr Therapeutics assumed with an Overweight at Barclays
Barclays assumed Crispr with an Overweight rating and a $29 price target, up from $22, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
12/21/17
PIPR
12/21/17
INITIATION
Target $30
PIPR
Overweight
Crispr Therapeutics assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff assumed coverage of Crispr Therapeutics with an Overweight rating and raised his price target for the shares to $30 from $24. The analyst sees "immense therapeutic potential" for the company's CRISPR/Cas9 gene editing technology.
12/22/17
12/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Waste Connections (WCN) initiated with a Buy at BofA/Merrill. 2. Carrizo Oil & Gas (CRZO) reinstated with a Neutral at Citi. 3. Crispr Therapeutics (CRSP) assumed with an Overweight at Piper Jaffray. 4. Sierra Bancorp (BSRR) initiated with a Market Perform at Fig Partners. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

FITB

Fifth Third

$30.89

-2.66 (-7.93%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Upgrade
Fifth Third rating change  »

Fifth Third upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTEX

OpenText

$34.10

0.1 (0.29%)

05:51
05/22/18
05/22
05:51
05/22/18
05:51
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.60

0.6 (1.00%)

05:50
05/22/18
05/22
05:50
05/22/18
05:50
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

M

Macy's

$34.60

0.63 (1.85%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Upgrade
Macy's rating change  »

Macy's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCR

NCR Corp.

$31.30

0.11 (0.35%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Conference/Events
NCR Corp. management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

, PFE

Pfizer

$35.79

0.15 (0.42%)

05:44
05/22/18
05/22
05:44
05/22/18
05:44
Hot Stocks
Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial »

Spark Therapeutics (ONCE)…

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

PFE

Pfizer

$35.79

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

FMC

FMC Corporation

$91.30

-0.22 (-0.24%)

05:41
05/22/18
05/22
05:41
05/22/18
05:41
Hot Stocks
FMC Corporation awarded contract for two fertilizer plants in India »

TechnipFMC, in consortium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.17

0.05 (0.98%)

05:40
05/22/18
05/22
05:40
05/22/18
05:40
Hot Stocks
Sprint partners with Scopeworker on multi-billion dollar 5G depoloyment »

Scopeworker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

05:39
05/22/18
05/22
05:39
05/22/18
05:39
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$20.00

0.14 (0.70%)

05:38
05/22/18
05/22
05:38
05/22/18
05:38
Initiation
Smartsheet initiated  »

Smartsheet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

VLRS

Volaris

$5.42

-0.05 (-0.91%)

05:19
05/22/18
05/22
05:19
05/22/18
05:19
Recommendations
Volaris analyst commentary  »

Volaris price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$72.08

1.4603 (2.07%)

05:16
05/22/18
05/22
05:16
05/22/18
05:16
Recommendations
Baxter analyst commentary  »

Baxter buybacks should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOCU

DocuSign

$43.06

-1.73 (-3.86%)

05:08
05/22/18
05/22
05:08
05/22/18
05:08
Initiation
DocuSign initiated  »

DocuSign initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

AROC

Archrock

$12.30

0.35 (2.93%)

05:07
05/22/18
05/22
05:07
05/22/18
05:07
Recommendations
Archrock analyst commentary  »

Archrock added to Alpha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$23.60

-0.065 (-0.27%)

05:05
05/22/18
05/22
05:05
05/22/18
05:05
Recommendations
Pure Storage analyst commentary  »

Pure Storage weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 07

    Jun

  • 12

    Jun

  • 10

    Jul

DOCU

DocuSign

$43.06

-1.73 (-3.86%)

05:02
05/22/18
05/22
05:02
05/22/18
05:02
Initiation
DocuSign initiated  »

DocuSign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

SSL

Sasol

$37.93

0.05 (0.13%)

05:00
05/22/18
05/22
05:00
05/22/18
05:00
Downgrade
Sasol rating change  »

Sasol downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

04:58
05/22/18
05/22
04:58
05/22/18
04:58
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALG

Alamo Group

$100.36

1.34 (1.35%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Alamo Group management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ALNA

Allena Pharmaceuticals

$15.99

-0.01 (-0.06%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTIC

CTI BioPharma

$4.79

-0.1 (-2.05%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
CTI BioPharma management to meet with Oppenheimer »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

PRA

ProAssurance

$40.10

0.15 (0.38%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
ProAssurance management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

SM

SM Energy

$27.18

0.52 (1.95%)

, APC

Anadarko

$71.69

1.12 (1.59%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
JPMorgan to hold a bus tour »

Denver Energy Bus Tour…

SM

SM Energy

$27.18

0.52 (1.95%)

APC

Anadarko

$71.69

1.12 (1.59%)

QEP

QEP Resources

$13.56

0.395 (3.00%)

WLL

Whiting Petroleum

$53.22

1.21 (2.33%)

HK

Halcon Resources

$5.49

-0.08 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 13

    Jun

  • 19

    Aug

SLD

Sutherland Asset Management

$15.35

0.1 (0.66%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Sutherland Asset Management management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 31

    May

TREX

Trex Company

$118.72

1.09 (0.93%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Trex Company management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

  • 24

    May

  • 11

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.